News headlines about Curis (NASDAQ:CRIS) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Curis earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.5121713626248 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern’s analysis:
- Cowen & Co. Keeps a Buy Rating on Curis Inc (CRIS) (analystratings.com)
- Notable Price Swings: Bellerophon Therapeutics, Inc. (BLPH), Curis, Inc. (CRIS) (talktraders.com)
- Curis, Inc. (CRIS) Top Loser within Investor Spotlight: (topdesertsafari.com)
- Contrasting Biogen (BIIB) & Curis (CRIS) (americanbankingnews.com)
- Curis (CRIS) Rating Reiterated by Cowen (americanbankingnews.com)
Several research firms recently issued reports on CRIS. Robert W. Baird cut their target price on Curis to $30.00 and set an “outperform” rating on the stock in a research note on Monday, May 7th. Zacks Investment Research upgraded shares of Curis from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Tuesday, May 8th. ValuEngine upgraded shares of Curis from a “sell” rating to a “hold” rating in a report on Thursday, May 31st. Cowen reiterated a “buy” rating on shares of Curis in a report on Monday, August 6th. Finally, SunTrust Banks decreased their price objective on shares of Curis to $8.00 and set a “buy” rating for the company in a report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Curis has an average rating of “Buy” and a consensus price target of $18.75.
Shares of CRIS stock traded up $0.01 during mid-day trading on Friday, reaching $1.61. 145,319 shares of the company’s stock traded hands, compared to its average volume of 266,878. Curis has a 12 month low of $1.57 and a 12 month high of $11.35. The company has a debt-to-equity ratio of 4.43, a current ratio of 3.01 and a quick ratio of 3.01. The company has a market cap of $53.09 million, a price-to-earnings ratio of -0.89 and a beta of 0.98.
Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.15. The firm had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.41 million. Curis had a negative net margin of 407.29% and a negative return on equity of 225.77%. equities research analysts expect that Curis will post -1.18 EPS for the current year.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Further Reading: Should you buy a closed-end mutual fund?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.